02 May 2018 NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers
02 May 2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
01 May 2018 AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
01 May 2018 Aptevo Therapeutics Announces IND Submission for APVO436
30 Apr 2018 Prometic Reports Positive Clinical Data from its Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
30 Apr 2018 FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy Based on Results from Phase 3 KEYNOTE-189 Trial as First-Line Treatment of Metastatic Nonsquamous NSCLC
30 Apr 2018 Ablynx completes patient recruitment in the phase IIb RESPIRE study of its inhaled anti-RSV nanobody ALX-0171
30 Apr 2018 FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
28 Apr 2018 Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
28 Apr 2018 Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy Volunteers
28 Apr 2018 UCB Announces Positive CHMP Opinion for CIMZIA® (certolizumab pegol) in Patients with Moderate-to-Severe Plaque Psoriasis
27 Apr 2018 FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
27 Apr 2018 ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
27 Apr 2018 Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs
27 Apr 2018 Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
27 Apr 2018 ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)
26 Apr 2018 BIOCAD: Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients
26 Apr 2018 ISA Pharmaceuticals’ ISA101 Studied in Phase II Oropharyngeal Cancer Combination Trial at MD Anderson Cancer Center
26 Apr 2018 Chugai Files Applications for HEMLIBRA® for the Treatment of Hemophilia A without Factor VIII Inhibitors and for Extension of Dosing Interval
26 Apr 2018 European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
25 Apr 2018 ADC Therapeutics Announces the Termination of its ADCT-502 Program Targeting HER2 Expressing Solid Tumors
25 Apr 2018 AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
24 Apr 2018 AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies
24 Apr 2018 European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3 KEYNOTE-189 Trial
24 Apr 2018 Connect Biopharmaceuticals Advances CBP-201, a Novel Monoclonal Antibody Against IL-4Rα, Into Clinical Development

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up